In-vitro metabolism of YM17E, an inhibitor of acyl coenzyme A:cholesterol acyltransferase, by liver microsomes in man

Journal of Pharmacy and Pharmacology

Volumn 48, Issue 10, 1996, Pages 1049-1056

  Uchida, Taisuke ^a   Watanabe, Takashi ^a   Van Hoogdalem, Ewoud J ^a   Higuchi, Saburo ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BIS [1 CYCLOHEPTYL 3 (PARA DIMETHYLAMINOPHENYL)UREIDO]METHYL]BENZENE DIHYDROCHLORIDE; 1,3 BIS[[1 CYCLOHEPTYL 3 (4 DIMETHYLAMINOPHENYL)UREIDO]METHYL]BENZENE; ACYLTRANSFERASE INHIBITOR; ALPHA NAPHTHOFLAVONE; ANTIBODY; CHOLESTEROL ACYLTRANSFERASE; COMPLEMENTARY DNA; CYTOCHROME P450; DRUG METABOLITE; ETHOXYRESORUFIN; KETOCONAZOLE; N DEMETHYLASE; NIFEDIPINE; OXYGENASE; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; LIVER METABOLISM; LIVER MICROSOME;

EID: 0029828648     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.1996.tb05898.x     Document Type: Article

References (36)

1. Bast, A., Scheefhalts, L. W. C., Noordhoek, J. (1982) Dose-dependent kinetics of aminopyrine metabolism in the rat caused by product inhibition and determined by capillary GLC. (1982) Pharmacology 25: 130-137
2. Bell, F. P. (1986) Arterial cholesterol esterification by acylcoA-cholesterol acyltransferase: its possible significance in atherogenesis and its inhibition by drug. In: Fears, R. (ed.) Pharmacological Control of Hyperlipidaemia. J. R. Prous Science Publishers, Barcelona, pp 409-422
3. Bourdi, M., Larrey, D., Nataf, J., Bernuau, J., Pessayre, D., Iwasaki, M., Guengerich, F. P., Beaune, P. H. (1990) Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P450IA2. J. Clin. Invest. 85: 1967-1973
4. Clarke, S. E., Baldwin, S. J., Bloomer, J. C., Ayrton, A. D., Sozio, R. S., Chenery, R. J. (1994) Lauric acid as a model substrate for the simultaneous determination of cytochrome P4502E1 and 4A in hepatic microsomes. Chem. Res. Toxicol. 7: 836-842
5. Goldstein, J. A., Faletto, M. B., Romkes-Sparks, M., Sullivan, T., Kitareewan, S., Raucy, J. L., Lasker, J. M., Ghanayem, B. I. (1994) Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33: 1743-1752
6. Guengerich, F. P., Martin, M. V., Beaune, P. H., Kremers, P., Wolff, T., Waxman, D. J. (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261: 5051-5060
7. Hainer, J. W., Terry, J. G., Connell, J. M., Zyruk, H., Jenkins, R. M., Shand, D. L., Gillies, P. J., Livak, K. J., Hunt, T. L., Crouse, J. R. (1994) Effect of the acyl-CoA:cholesterol acyltransferase inhibitor Dup 128 on cholesterol absorption and serum cholesterol in humans. Clin. Pharmacol. Ther. 56: 65-74
8. Harris, W. S., Dujovne, C. A., Bergmann, K. V., Neal, J., Akester, J., Windsor, S. L, Greene, D., Look, Z. (1990) Effects of the ACAT inhibitor CL277,082 on cholesterol metabolism in humans. Clin. Pharmacol. Ther. 48: 189-94
9. Heider, J. G., Pickens, C. E., Kelly, L. A. (1983) Role of acyl CoA: cholesterol acyltransferase in cholesterol absorption and its inhibition by 57-118 in the rabbit. J. Lipid Res. 24: 1127-1134
10. Iizumi, Y., Yanagita, Y., Masuyama, Y., Ohtsuka, H., Kakuta, H., Fujimari, N., Itoh, N., Matsuda, K., Ohata, I. (1991) Lipid-lowering and anti-atherosclerotic activity of YM17E, an inhibitor of acylCoA:cholesterol acyltransferase (ACAT) in animal models. 9th Int. Symp. Atherosclerosis, Rosemont, IL, USA, Abstract 96
11. Ito, N., Matsuda, K., Yasunaga, T., Araki, T., Iwaoka, K., Iizumi, Y., Ohhata, I. (1991) Synthesis and hypocholesterolemic activity of phenylene and pyridylene diurea derivatives as ACAT inhibitors. 202nd ACS National Meeting, New York, NY, USA, Abstract 109
12. Kato, R., Yamazoe, Y., Yasumori, T. (1992) Polymorphism in stereoselective hydroxylation of mephenytoin and hexobarbital by Japanese liver samples in relation to cytochrome P450 human-2 (CYPIIC9). Xenobiotica 22: 1083-1092
13. Knodell, R. G., Dubey, R. K., Wilkinson, G. R., Guengerich, F. P. (1988) Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation. J. Pharmacol. Exp. Ther. 245: 845-849
14. Krause, B. R., Anderson, M., Bisgaier, C. L., Bocan, T., Bousley, R., DeHart, P., Essenburg, A., Hamelehle, K., Homan, R., Kieft, K., McNally, W., Stanfield, R., Newton, R. S. (1993) In vivo evidence that the lipid-regulating activity of the ACAT inhibitor CI-976 in rats is due to inhibition of both intestinal and liver ACAT. J. Lipid Res. 34: 279-294
15. Kronbach, T., Mathys, D., Gut, J., Catin, T., Meyer, U. R. (1987) Highperformance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal. Biochem. 162: 24-32
16. Kupfer, A., Schmid, B., Pfaff, G. (1986) Pharmacokinetics of dextromethorphan O-demethylation in man. Xenobiotica 16: 421-433
17. Largis, E. E., Wang, C. H., DeVries, V. G., Schaffer, S. A. (1989) CL 277,082: a novel inhibitor of ACAT-catalyzed cholesterol esterification and cholesterol absorption. J. Lipid Res. 30: 681-690
18. Lee, Q. P., Fantel, A. G., Juchau, M. R. (1991) Human embryonic cytochrome P450s: phenoxazone ethers as probes for expression of functional isoforms during organogenesis. Biochem. Pharmacol. 42: 2377-2385
19. Matsuda, K. (1994) ACAT inhibition as antiatherosclerotic agents: compounds and mechanisms. Med. Res. Rev. 14: 271-305
20. Maurice, M., Pichard, L., Daujat, M., Fabre, I., Joyeux, H., Domergue, J., Maurel, P, (1992) Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J. 6: 752-758
21. Otton, S. V., Crewe, H. K., Lennard, M. S., Tucker, G. T., Woods, H. F. (1988) Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. 247: 242-247
22. Peck, R. W., Wiggs, R., Posner, J. (1995) The tolerability, pharmacokinetics and lack of effect on plasma cholesterol of 447C88, an acylCoA:cholesterol acyl transferase (ACAT) inhibitor with low bioavailability, in healthy volunteers. Eur. J. Clin. Pharmacol. 49: 243-249
23. Peter, R., Bocker, R., Beaune, P. H., Iwasaki, M., Guengerich, F. P., Yang, C. S. (1990) Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem. Res. Toxicol. 3: 566-573
24. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., Guengerich, F. P. (1994) Interindividual variations in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270: 414-423
25. Siddoway, L. A., Thompson, K. A., McAllister, C. B., Wang, T., Wilkinson, G. R., Roden, D. M., Woosley, R. L. (1987) Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 75: 785-791
26. Suzuki, T., Fujita, S., Kawai, R. (1984) Precursor-metabolite interaction in the metabolism of lidocaine. J. Pharm. Sci. 73: 136-138
27. Tse, F. L. S., Jaffe, J. M. (1988) Influence of high-fat meal on the absorption of a silicon-containing amide, an inhibitor of acyl-CoA:cholesterol acyltransferase, in man. Biopharm. Drug Dispos. 9: 201-210
28. Uchida, T., Usui, T., Teramura, T., Watanabe, T., Higuchi, S. (1993a) Metabolic N-demethylation of 1,3-bis[[1-cycloheptyl-3-(p-dimethylaminophenyl)ureido]methyl]benzene dihydrochloride, a novel acylcoenzyme A:cholesterol acyltransferase inhibitor. Drug. Metab. Dispos. 21: 524-529
29. Uchida, T., Usui, T., Watanabe, T., Higuchi, S. (1993b) Simultaneous determination of a new inhibitor of acyl CoA:cholesterol acyltransferase, YM17E, and five metabolites using high-performance liquid chromatography with electrochemical detection. J. Chromatogr. Biomed. Appl. 613: 179-183
30. Uchida, T., Nakamura, E., Usui, T., Imasaki, H., Kawakami, R., Watanabe, T., Higuchi, S. (1994) Disposition and metabolism of a novel diurea inhibitor of acyl CoA:cholesterol acyltransferase (YM17E) in the rat and dog. Xenobiotica 24: 1223-1236
31. Uchida, T., Usui, T., watanabe, T., Higuchi, S., Nakata, M., Maezawa, K., Kikawa, Y., tsunoo, M., Nakaya, N., Goto, Y. (1996) Pharmacohinetic properties of YM17E, an inhibitor of acyl CoA:cholesterol acyl transferase, and serum cholesterol levels in healthy volunteers. eur. J. clin. Pharmacol. In press
32. Veronese, M. E., Doecke, C. J., Mackenzie, P. I., McManus, M. E., Miners, J, O., Rees, D. L. P., Gasser, R., Meyer, U. A., Birkett, D. J. (1993) Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem. J. 289: 533-538
33. Watkins, P. B., Erighton, S. A., Maurel, P., Schuetz, E. G., Mendez-Picon, G., Parker, G. A., Guzelian, P. S. (1985) Identification of an inducible form of cytochrome P-450 in human liver. Proc. Natl. Acad. Sci. 82: 6310-6314
34. Waxman, D. J., Attisano, C., Guengerich, F. P., Lapenson, D. P. (1988) Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6β-hydroxylase cytochrome P-450 enzyme. Arch. Biochem. Biophys. 263: 424-436
35. Waxman, D. J., Lapenson, D. P., Aoyama, T., Gelboin, H. V., Gonzalez, F. J., Korzekwa, K. (1991) Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch. Biochem. Biophys. 290: 160-166
36. Yamano, S., Tatsuno, J., Gonzalez, F. J. (1990) The CYP2A3 gene product catalyses coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29: 1322-1329